Chapter Four · failure evidence
What Pharmacological Receptor Modulation got wrong, from 13 dissertations
The records describe various experimental and therapeutic challenges encountered during pharmacological receptor modulation studies. Investigators faced difficulties with ligand optimization, unintended partial agonism, subtherapeutic dosing regimens, and inadequate systemic delivery of free agonists. These records come from PhD theses at 9 institutions, 2021 to 2026. Each links to its thesis. They were extracted by language models reading the full text, so treat each as a lead to read, not a verdict.
Candidate ligand design and structural modification fail to achieve required pharmacological profiles
Scaffold methylation and allosteric optimization led to steric hindrance or inferior binding affinity compared to orthosteric reference antagonists. Additionally, alternative and dual-acting agonists failed to achieve balanced independent receptor binding or failed to provide downstream functional protection despite inducing target genes.
Tried and failed
nitrogen methylation of heterocyclic antagonist scaffold applied to adenosine receptor antagonists. Outcome: worse than baseline. Reason: regioisomeric methylation caused steric hindrance preventing crucial hydrogen bonding with receptor residue N6.55
Considered and rejected
Considered and rejected: Rejected substituting ATRA with light-stable pan-RAR agonist TTNPB because TTNPB failed to elicit functional Mtb restriction despite robust target gene induction.
Improving and understanding macrophage restriction of Mycobacterium tuberculosis infection · Harvard
Lost to a baseline
Lead NAM 40r EP2 binding affinity (Ki = 31 nM) was lower than orthosteric antagonists TG4-155 (Ki = 9.9 nM) and PF-04418948 (Ki = 16 nM).
Design, synthesis and characterisation of novel allosteric modulators for the prostaglandin EP 2 receptor · University of Nottingham Repository
Considered and rejected
Considered and rejected: Decided against unimolecular dual GLP-1R/GCGR agonists (e.g. oxyntomodulin analogues) due to failure to optimize independent receptor binding and fixed ratio limitations
Unintended partial agonism interferes with antagonist efficacy and assay utility
Molecules selected as neutral antagonists or reference agonists exhibited unexpected partial agonist activity in target tissues. This intrinsic activity prevented full repression of receptor-dependent transcription, hindered antagonist development, and narrowed the assay dynamic response window.
Tried and failed
neutral receptor antagonist treatment applied to constitutively active steroid receptor-dependent cancer. Outcome: no signal. Reason: exhibited partial agonist activity instead of repressing hormone-independent transcription
Considered and rejected
Considered and rejected: Rejected using GIP28 as an in vivo GIPR antagonist after identifying partial agonist activity in dispersed islets and in vivo IPGTT
Considered and rejected
Considered and rejected: Rejected using dopamine as the control agonist in favor of quinpirole due to dopamine displaying apparent partial agonism and a smaller response window at D3R.
An investigation into ligand selectivity between dopamine receptor subtypes, biased agonism, and protean agonism · University of Nottingham Repository
Free small molecule agonists fail to achieve adequate systemic antitumor efficacy compared to formulated baselines
Systemic delivery of unformulated free agonists resulted in insufficient tumor accumulation and immune activation to control tumor growth or prolong survival. As a consequence, free agonist regimens failed to match the therapeutic antitumor performance of formulated drugamer delivery systems.
Tried and failed
systemic administration of free small-molecule agonist applied to syngeneic colorectal carcinoma model. Outcome: no signal. Reason: free agonist lacked sufficient tumor accumulation or immune activation to inhibit tumor growth or improve survival
From Observation to Perturbation: Dissecting Cell State Transitions in Immune and Cancer Cells · MIT
Lost to a baseline
Free STING agonist treatment matched STING drugamers in inducing splenic antigen-specific CD8+ T cells but failed to improve therapeutic antitumor efficacy in vivo.
Synthetic Polymers To Address Multiscale Drug Delivery Challenges For Cancer Immunotherapy · ResearchWorks
Subtherapeutic dosing regimens and insufficient durations fail to induce phenotypic responses
Low-dose receptor agonist administrations failed to produce statistically significant reductions in body weight in vivo. These protocols proved subtherapeutic over the tested timeframes and required dose escalation to establish phenotypic changes.
Tried and failed
Low-dose glucagon receptor agonist co-treatment applied to in vivo body weight reduction. Outcome: no signal. Reason: The administered dose was subtherapeutic and required dose escalation to achieve phenotypic weight reduction
Tried and failed
short-term GLP-1 receptor agonist administration applied to murine body weight reduction. Outcome: no signal. Reason: two weeks of daily low-dose treatment was insufficient to induce statistically significant body weight divergence
Left open by the authors
Problems the authors named and did not get to.
Left open
Meta-analyze published preclinical comparative studies evaluating DOR, MOR, and KOR agonists across analgesic efficacy and adverse effect profiles. Blocker: None
Delta Opioid Receptor Agonist Potential Use in Mitigating Opioid Withdrawal Symptoms · Harvard
Left open
Meta-analyze dose-response curves and administration routes of delta opioid receptor agonists across preclinical withdrawal assays. Blocker: None
Delta Opioid Receptor Agonist Potential Use in Mitigating Opioid Withdrawal Symptoms · Harvard
Left open
Collect functional efficacy data (EC50/Emax or agonist/antagonist classification) from pharmacological databases to refine candidate psychedelic receptor scoring. Blocker: None
Exploring Novel Psychedelic Treatments for Major Depression Through an Analysis of Key Receptor Sites · UT Austin
Left open
Optimize the in vitro functional assay resolution to distinguish between full and partial M3 muscarinic receptor agonists. Blocker: Requires wet-lab experimental pharmacology facilities and assay optimization protocols
Ligand-Induced Activation of the M3-Muscarinic Acetylcholine Receptor Liganden-induzierte Aktivierung des M3-muskarinischen Acetylcholinrezeptors · open_UMR Marburg DSpace 10.0
Checking a claim in this area?
We can run the same search on any method or claim. If nothing turns up, we will say so, and that proves nothing on its own.